ARKG vs. BIB

Last updated Jun 4, 2026

ARKG (ARK Genomic Revolution Multi-Sector ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) are both exchange-traded funds - ARKG is a Health & Biotech Equities fund actively managed by ARK, while BIB is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%). ARKG is actively managed, while BIB is passively managed. Over the past 10 years, ARKG returned 7.22%/yr vs 5.68%/yr for BIB. A 0.78 correlation means they provide meaningful diversification when combined. ARKG charges 0.75%/yr vs 0.95%/yr for BIB.

Performance

ARKG vs. BIB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and ProShares Ultra Nasdaq Biotechnology (BIB). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ARKG achieves a 17.09% return, which is significantly higher than BIB's -0.51% return. Over the past 10 years, ARKG has outperformed BIB with an annualized return of 7.22%, while BIB has yielded a comparatively lower 5.68% annualized return.

ARKG

• 1D: -0.24%
• 1M: 10.92%
• YTD: 17.09%
• 6M: 10.02%
• 1Y: 53.35%
• 3Y*: 0.67%
• 5Y*: -15.72%
• 10Y*: 7.22%

BIB

• 1D: 3.49%
• 1M: -3.84%
• YTD: -0.51%
• 6M: -3.00%
• 1Y: 76.61%
• 3Y*: 14.49%
• 5Y*: -1.02%
• 10Y*: 5.68%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ARKG vs. BIB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARKG ARK Genomic Revolution Multi-Sector ETF	17.09%	23.04%	-28.24%	16.22%	-53.90%	-33.92%	180.40%	44.00%	-1.26%	46.61%
BIB ProShares Ultra Nasdaq Biotechnology	-0.51%	59.21%	-9.84%	-1.06%	-28.85%	-6.02%	39.79%	46.71%	-24.93%	40.49%

Correlation

The correlation between ARKG and BIB is 0.66, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.66
Correlation (3Y) Calculated over the trailing 3-year period	0.74
Correlation (5Y) Calculated over the trailing 5-year period	0.78
Correlation (10Y) Calculated over the trailing 10-year period	0.79
Correlation (All Time) Calculated using the full available price history since Nov 3, 2014	0.78

The correlation between ARKG and BIB shifts across timeframes, from 0.66 (1 year) to 0.79 (10 years), reflecting how their relationship changes across market environments.

ARKG vs. BIB - Sectors Allocation Comparison

Sectors	ARKG	BIB
Healthcare	99.2%	63.8%
Financial Services	0.5%	7.0%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

ARKG vs. BIB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARKG

ARKG Risk / Return Rank: 35
ARKG Sharpe Ratio Rank: 35
ARKG Sortino Ratio Rank: 37
ARKG Omega Ratio Rank: 32
ARKG Calmar Ratio Rank: 38
ARKG Martin Ratio Rank: 31

BIB

BIB Risk / Return Rank: 63
BIB Sharpe Ratio Rank: 57
BIB Sortino Ratio Rank: 53
BIB Omega Ratio Rank: 48
BIB Calmar Ratio Rank: 84
BIB Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARKG vs. BIB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARKG	BIB	Difference
Sharpe ratio: Return per unit of total volatility	1.31	1.95	-0.64
Sortino ratio: Return per unit of downside risk	1.99	2.58	-0.59
Omega ratio: Gain probability vs. loss probability	1.22	1.30	-0.08
Calmar ratio: Return relative to maximum drawdown	1.95	4.55	-2.60
Martin ratio: Return relative to average drawdown	4.67	14.49	-9.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARKG vs. BIB - Sharpe Ratio Comparison

The current ARKG Sharpe Ratio is 1.31, which is lower than the BIB Sharpe Ratio of 1.95. The chart below compares the historical Sharpe Ratios of ARKG and BIB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ARKG	BIB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.31	1.95	-0.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.35	-0.02	-0.32
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.18	0.12	+0.05
Sharpe Ratio (All Time) Calculated using the full available price history	0.13	0.34	-0.20

Drawdowns

ARKG vs. BIB - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than BIB's maximum drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for ARKG and BIB.

Drawdown Indicators

	ARKG	BIB	Difference
Max Drawdown Largest peak-to-trough decline	-83.59%	-67.24%	-16.35%
Max Drawdown (1Y) Largest decline over 1 year	-27.51%	-16.92%	-10.59%
Max Drawdown (3Y) Largest decline over 3 years	-51.96%	-45.30%	-6.66%
Max Drawdown (5Y) Largest decline over 5 years	-80.18%	-65.86%	-14.32%
Max Drawdown (10Y) Largest decline over 10 years	-83.59%	-66.20%	-17.39%
Current Drawdown Current decline from peak	-69.65%	-26.85%	-42.80%
Average Drawdown Average peak-to-trough decline	-35.87%	-32.74%	-3.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.46%	5.30%	+6.16%

Volatility

ARKG vs. BIB - Volatility Comparison

The current volatility for ARK Genomic Revolution Multi-Sector ETF (ARKG) is 11.90%, while ProShares Ultra Nasdaq Biotechnology (BIB) has a volatility of 13.91%. This indicates that ARKG experiences smaller price fluctuations and is considered to be less risky than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARKG	BIB	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.90%	13.91%	-2.01%
Volatility (6M) Calculated over the trailing 6-month period	28.77%	30.57%	-1.80%
Volatility (1Y) Calculated over the trailing 1-year period	41.12%	39.59%	+1.53%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.61%	43.56%	+2.05%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	41.12%	46.50%	-5.38%

ARKG vs. BIB - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is lower than BIB's 0.95% expense ratio.

Dividends

ARKG vs. BIB - Dividend Comparison

ARKG has not paid dividends to shareholders, while BIB's dividend yield for the trailing twelve months is around 0.62%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARKG ARK Genomic Revolution Multi-Sector ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.62%	0.85%	3.14%	0.82%	1.34%
BIB ProShares Ultra Nasdaq Biotechnology	0.62%	0.77%	1.69%	0.07%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both ARKG and BIB in my portfolio?

ARKG and BIB have a correlation of 0.66, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ARKG or BIB?

BIB has higher volatility (13.91%) compared to ARKG (11.90%). In terms of maximum drawdown, ARKG dropped -83.59% vs BIB's -67.24%.

Which ETF is better, ARKG or BIB?

On 10-year performance, ARKG leads with 7.22% vs 5.68% for BIB. On fees, ARKG is cheaper at 0.75% per year. On volatility, ARKG has been the lower-risk option at 11.90%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, ARKG or BIB?

Over the 10-year period, ARKG has performed better with a 7.22% return vs 5.68%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, ARKG or BIB?

ARKG is cheaper with a 0.75% expense ratio, compared with 0.95% for BIB.

Which ETF pays a higher dividend yield, ARKG or BIB?

BIB has the higher dividend yield at 0.62%, compared with 0.00% for ARKG.

What is the main difference between ARKG and BIB?

ARKG is categorized as Health & Biotech Equities, while BIB is Leveraged Equities. They also come from different issuers: ARK and ProShares. Their fees differ too: 0.75% for ARKG and 0.95% for BIB.

Which has better risk-adjusted returns?

BIB currently has the higher Sharpe Ratio (1.95 vs 1.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.